HR-2678-119
Referred to the House Committee on Energy and Commerce.
Sponsored by Brian Fitzpatrick (R-PA)
What it does
This bill would authorize $20 million per year for fiscal years 2026 through 2030 (totaling $100 million) for the National Institute of Neurological Disorders and Stroke (NINDS) to conduct or support comprehensive research on unruptured intracranial aneurysms. The research would be required to study a broader and more diverse patient population, including variation by age, sex, and race. Any new funding would supplement — not replace — existing federal spending on brain aneurysm research.
Who benefits
The estimated 6.8 million Americans living with an unruptured brain aneurysm, who could benefit from improved detection and treatment options. Women, who develop aneurysms at a higher rate than men (3:2 ratio). African American and Hispanic populations, who face disproportionately higher rupture rates and are specifically included in the mandated research population. Survivors of ruptures and their caregivers, who bear significant financial and neurological burdens. Neurological researchers and academic medical centers that would receive grant funding. Hospitals and ICUs that treat rupture patients, who could benefit from improved clinical protocols.
Who is hurt
Researchers and programs competing for NINDS funding, if appropriators offset this authorization against other neurological research priorities. Taxpayers who bear the cost of the $100 million authorization. Other disease advocacy communities that may view this targeted earmark as setting a precedent that disadvantages conditions without similar legislative champions. There are no direct regulatory burdens imposed on any private party.
Supporters argue
Supporters argue that brain aneurysms affect roughly 1 in 50 Americans and kill approximately 15,000 people annually, yet the federal government spends only about $2.94 per affected person per year on research — a stark mismatch between disease burden and funding. They contend that the existing International Study on Unruptured Intracranial Aneurysms has already demonstrated that targeted research produces clinically actionable results, and that expanding the study population to include more women and racial minorities would address documented disparities in rupture rates and outcomes.
Opponents argue
Opponents argue that Congress should not direct disease-specific research funding through standalone legislation, as this bypasses the NIH's peer-review process for allocating research dollars based on scientific merit and opportunity. They contend that the $100 million authorization, while modest, sets a precedent for politically driven earmarks that could distort research priorities across NINDS and NIH broadly — and note that the bill authorizes but does not appropriate funds, meaning it may never result in actual spending without a separate appropriations action.
Constitutional context
Congress has broad authority to fund scientific research through the Taxing and Spending Clause (Art. I, §8, cl. 1), which permits spending for the general welfare. This bill raises no significant constitutional questions — it is a straightforward authorization of appropriations to an existing federal agency (NINDS) for a defined research purpose, well within established congressional spending power.
Checks and balances
Congress gains authority to direct NINDS research priorities; the Appropriations Committees retain the ultimate check, as the authorization does not guarantee actual funding without a separate appropriations act.
Historical precedent
Congress has previously passed disease-specific research authorization bills targeting NINDS and other NIH institutes, such as the National Alzheimer's Project Act (2011), which similarly directed a federal agency to prioritize and coordinate research on a specific neurological condition.